Zobrazeno 1 - 10 of 169 pro vyhledávání: '"Yechiel A, Hekster"'
1
Akademický článek
Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis
Autor: Stephanie S. Weinreich, Charlotte Vrinten, Marja R. Kuijpers, Alexander F. Lipka, Kirsten J. M. Schimmel, Erik W. van Zwet, Christine Gispen-de Wied, Yechiel A. Hekster, Jan J. G. M. Verschuuren, Martina C. Cornel
Publikováno v: Orphanet Journal of Rare Diseases, Vol 12, Iss 1, Pp 1-18 (2017)
Abstract Background Inexpensive medicines with a long history of use may currently be prescribed off-label for rare indications. Reimbursement is at the discretion of health insurance companies, and may be unpredictable. The example addressed was eph
Externí odkaz: https://doaj.org/article/89b8aba7bbad472cb91c27a0db2bdc16
Zobrazit plný text záznamu
2
Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis
Autor: Erik W. van Zwet, Kirsten J. M. Schimmel, Yechiel A. Hekster, Martina C. Cornel, Jan J.G.M. Verschuuren, Christine C. Gispen-de Wied, Stephanie S Weinreich, Charlotte Vrinten, Alexander F. Lipka, Marja R. Kuijpers
Publikováno v: Weinreich, S S, Vrinten, C, Kuijpers, M R, Lipka, A F, Schimmel, K J M, Van Zwet, E W, Gispen-De Wied, C, Hekster, Y A, Verschuuren, J J G M & Cornel, M C 2017, ' Aggregated N-of-1 trials for unlicensed medicines for small populations : an assessment of a trial with ephedrine for myasthenia gravis ', Orphanet Journal of Rare Diseases, vol. 12, no. 1, 88 . https://doi.org/10.1186/s13023-017-0636-y
Orphanet Journal of Rare Diseases, Vol 12, Iss 1, Pp 1-18 (2017)
Orphanet Journal of Rare Diseases
Orphanet Journal of Rare Diseases, 12(1):88. BioMed Central
Orphanet Journal of Rare Diseases, 12
Background Inexpensive medicines with a long history of use may currently be prescribed off-label for rare indications. Reimbursement is at the discretion of health insurance companies, and may be unpredictable. The example addressed was ephedrine as
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff4bd4bfed65f26a37c7c77f6ab1aac
https://doi.org/10.1186/s13023-017-0636-y
Zobrazit plný text záznamu
3
Ephedrine treatment for autoimmune myasthenia gravis
Autor: Erik W. van Zwet, Kirsten J. M. Schimmel, Jan J.G.M. Verschuuren, Martina C. Cornel, Yechiel A. Hekster, Stephanie S Weinreich, Marja R. Kuijpers, Alexander F. Lipka, Charlotte Vrinten
Publikováno v: Neuromuscular Disorders, 27(3), 259-265. Elsevier Limited
Lipka, A F, Vrinten, C, van Zwet, E W, Schimmel, K J M, Cornel, M C, Kuijpers, M R, Hekster, Y A, Weinreich, S S & Verschuuren, J J G M 2017, ' Ephedrine treatment for autoimmune myasthenia gravis ', Neuromuscular Disorders, vol. 27, no. 3, pp. 259-265 . https://doi.org/10.1016/j.nmd.2016.11.009
Neuromuscular Disorders, 27(3), 259-265
We studied the effect and safety of ephedrine as add-on treatment for patients with myasthenia gravis with acetylcholine receptor antibodies (AChR MG), who do not sufficiently respond to standard treatment. Four patients with AChR MG were included in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad945b2ea9605ec22ae06db64161452e
https://hdl.handle.net/1887/114492
Zobrazit plný text záznamu
4
The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis
Autor: Aatke van den Maas, Piet L. C. M. van Riel, Alfons A den Broeder, H Bart Benraad, Bart J F van den Bemt, Frank H J van den Hoogen, Gertjan Wolbink, Yechiel A. Hekster
Publikováno v: British Journal of Clinical Pharmacology. 76:939-945
AIM: Early prediction of (non-)response to infliximab therapy can improve therapeutic benefit by avoiding unnecessary periods of high disease activity during ineffective therapy. This prospective cohort study therefore aimed to study the predictive v
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d65c4e619e785993c1b9d4a80973d840
https://doi.org/10.1111/bcp.12142
Zobrazit plný text záznamu
5
Controlled release of morphine from a poloxamer 407 gel
Autor: Mark M.P.M. Jansen, David M. Burger, Jacques M. Verzijl, Yechiel A. Hekster
Publikováno v: International Journal of Pharmaceutics, 452, 266-9
International Journal of Pharmaceutics, 452, 1-2, pp. 266-9
Item does not contain fulltext Treatment of painful ulcers is discouraging. Topical morphine has been described as a useful therapeutic adjunct in some patients. In the development of a new analgesic product, we studied the in vitro release character
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c54baf8b09ed2b04253ad0cf3d386f1c
https://hdl.handle.net/2066/119254
Zobrazit plný text záznamu
7
Requirements for generic anti-epileptic medicines: a regulatory perspective
Autor: Christine C. Gispen-de Wied, Eugène van Puijenbroek, Jan Welink, Marc Maliepaard, Frits J.F. Lekkerkerker, Arnoud C. Kappelle, Yechiel A. Hekster, André J.A. Elferink
Publikováno v: Journal of Neurology, 256, 12, pp. 1966-71
Journal of Neurology
Journal of Neurology, 256(12), 1966-1971. SPRINGER HEIDELBERG
Journal of Neurology, 256, 1966-71
Bioequivalence requirements are very strict and are the basis of therapeutic equivalence between innovators and generics. Therefore, switching to a generic anti-epileptic medicine appears to be safe based on pharmacokinetic grounds, and does not appe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c65fc984cdcdfb8ddad619baa1729ce1
https://doi.org/10.1007/s00415-009-5231-2
Zobrazit plný text záznamu
8
Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study
Autor: G.F. Snijders, Bart Benraad, F.H.J. van den Hoogen, B. van den Bemt, Yechiel A. Hekster, A.A. den Broeder, P.L.C.M. van Riel, Gertjan Wolbink
Publikováno v: Annals of the Rheumatic Diseases, 67, 1697-701
Annals of the Rheumatic Diseases, 67, 12, pp. 1697-701
Contains fulltext : 70888.pdf (Publisher’s version ) (Closed access) OBJECTIVES: In clinical trials only a small subset of patients with rheumatoid arthritis (RA) benefits from higher than standard dose of infliximab (>3 mg/kg/8 weeks). However, do
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2644e27c9ce6f2df419bcdf3c860b543
https://doi.org/10.1136/ard.2007.083683
Zobrazit plný text záznamu
9
A Cost-Effectiveness Decision Model for Antiepileptic Drug Treatment in Newly Diagnosed Epilepsy Patients
Autor: Willy O. Renier, Arjo J. Boendermaker, P.D. Knoester, C.L.P. Deckers, Hans Severens, Toine Keyser, Yechiel A. Hekster, Marc C. T. F. M. de Krom, Eveline H. Termeer, Irene A. W. Kotsopoulos
Publikováno v: Value in Health, 10, 3, pp. 173-82
Value in Health, 10(3), 173-182. Elsevier Ltd.
Value in Health, 10, 173-82
Contains fulltext : 53088.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To establish cost-effectiveness of antiepileptic drug (AED) treatment strategies of newly diagnosed patients with epilepsy. METHODS: A decision analysis was carried out
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fc75b5086246f9b581a4b5d6dfa4c11
https://doi.org/10.1111/j.1524-4733.2007.00167.x
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje